Antineoplastics
1
Reactions 1469, p6 - 14 Sep 2013 Antineoplastics Neutropenia, nausea and vomiting: case report A 37-year-old man developed neutropenia, nausea and vomiting while receiving antineoplastics for metastatic urachal adenocarcinoma [durations of treatment to reactions onset and outcomes not stated; not all routes stated]. The man underwent a partial cystectomy with resection of urachus and umbilicus in 2002 for a mucinous urachal adenocarcinoma. Four years later, he was diagnosed with metastatic disease. He received chemotherapy on days 1 and 14, consisting of fluorouracil 400 mg/m 2 as an IV bolus followed by fluorouracil 2400mg as a continuous IV infusion over 46h and irinotecan 90 mg/m 2 . Three cycles were administered, during which time he developed persistent grade 2 neutropenia. The man’s chemotherapy schedule was adjusted to days 1 and 21, and he began receiving granulocyte colony-stimulating factor. The metastases were surgically removed, but recurrence of the urachal carcinoma was seen at 6 months’ follow-up. He received chemotherapy on days 1 and 14, consisting of fluorouracil 400 mg/m 2 as an IV bolus followed by fluorouracil 1200mg as a continuous IV infusion over 46h, irinotecan 90 mg/m 2 and bevacizumab 5 mg/kg. During treatment, he developed mild vomiting. He subsequently received 3 cycles of chemotherapy associated with capecitabine 2000 mg/m 2 /day on days 1–14 and oxaliplatin 130 mg/m 2 on days 1–21. Grade 3 nausea and vomiting was observed. In June 2009, he underwent right pneumonectomy with rib resection, but died during surgery due to haemorrhagic shock. Author comment: "Tolerance was acceptable, despite a grade 2 neutropenia. . . Tolerance was fair with mild vomiting and no changes in hematologic parameters." Piegay F, et al. Combined modalities treatment of pulmonary metastasis from an urachal adenocarcinoma. Rare Tumors 5: 113-115, No. 3, 12 Jul 2013. Available from: URL: http://dx.doi.org/10.4081/rt.2013.e32 - France 803092835 1 Reactions 14 Sep 2013 No. 1469 0114-9954/13/1469-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1469, p6 - 14 Sep 2013
Antineoplastics
Neutropenia, nausea and vomiting: case reportA 37-year-old man developed neutropenia, nausea and
vomiting while receiving antineoplastics for metastatic urachaladenocarcinoma [durations of treatment to reactions onset andoutcomes not stated; not all routes stated].
The man underwent a partial cystectomy with resection ofurachus and umbilicus in 2002 for a mucinous urachaladenocarcinoma. Four years later, he was diagnosed withmetastatic disease. He received chemotherapy on days 1 and14, consisting of fluorouracil 400 mg/m2 as an IV bolusfollowed by fluorouracil 2400mg as a continuous IV infusionover 46h and irinotecan 90 mg/m2. Three cycles wereadministered, during which time he developed persistentgrade 2 neutropenia.
The man’s chemotherapy schedule was adjusted to days 1and 21, and he began receiving granulocyte colony-stimulatingfactor. The metastases were surgically removed, butrecurrence of the urachal carcinoma was seen at 6 months’follow-up. He received chemotherapy on days 1 and 14,consisting of fluorouracil 400 mg/m2 as an IV bolus followedby fluorouracil 1200mg as a continuous IV infusion over 46h,irinotecan 90 mg/m2 and bevacizumab 5 mg/kg. Duringtreatment, he developed mild vomiting. He subsequentlyreceived 3 cycles of chemotherapy associated withcapecitabine 2000 mg/m2/day on days 1–14 and oxaliplatin130 mg/m2 on days 1–21. Grade 3 nausea and vomiting wasobserved. In June 2009, he underwent right pneumonectomywith rib resection, but died during surgery due tohaemorrhagic shock.
Author comment: "Tolerance was acceptable, despite agrade 2 neutropenia. . . Tolerance was fair with mild vomitingand no changes in hematologic parameters."Piegay F, et al. Combined modalities treatment of pulmonary metastasis from anurachal adenocarcinoma. Rare Tumors 5: 113-115, No. 3, 12 Jul 2013. Availablefrom: URL: http://dx.doi.org/10.4081/rt.2013.e32 - France 803092835
1
Reactions 14 Sep 2013 No. 14690114-9954/13/1469-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
